NASDAQ:ABCL
AbCellera Biologics Inc.
- Stock
Last Close
3.10
26/07 20:00
Market Cap
823.35M
Beta: −0.12
Volume Today
692.61K
Avg: 1.63M
PE Ratio
−11.06
PFCF: −20.83
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | 704K - | 1.54M 118.75% | 1.60M 4.03% | 1.32M 17.63% | |||
average payables | 1.58M - | 10.82M 584.73% | 26.01M 140.30% | 32.58M 25.27% | 29.33M 9.99% | ||
average receivables | 4.27M - | 108.81M 2,446.58% | 186.91M 71.78% | 99.58M 46.72% | 51.49M 48.30% | ||
book value per share | 0.05 - | 0.05 11.69% | 5.22 10,861.62% | 3.72 28.70% | 4.33 16.31% | 3.98 7.89% | |
capex per share | -0.02 - | -0.02 24.69% | -0.09 396.76% | -0.21 129.97% | -0.25 20.25% | -0.27 5.15% | |
capex to depreciation | -5.78 - | -2.16 62.57% | -2.78 28.63% | -3.39 21.73% | -2.20 35.22% | -2.51 14.29% | |
capex to operating cash flow | -1.49 - | -1.48 0.33% | -0.65 56.42% | -0.24 63.04% | -0.26 9.62% | 1.77 774.30% | |
capex to revenue | -0.60 - | -0.34 42.72% | -0.06 81.72% | -0.16 147.55% | -0.15 3.92% | -2.04 1,261.75% | |
cash per share | 0.05 - | 0.04 27.68% | 3.73 10,543.94% | 2.62 29.75% | 3.11 18.62% | 2.63 15.42% | |
days of inventory on hand | 18.93 - | 13.41 29.18% | 8.42 37.23% | ||||
days payables outstanding | 269.01 - | 256.75 4.56% | 182.13 29.06% | ||||
days sales outstanding | 172.25 - | 137.61 20.11% | 333.82 142.58% | 156.21 53.21% | 29.02 81.42% | 618.00 2,029.65% | |
debt to assets | 0.16 - | 0.29 83.16% | 0.01 97.93% | 0.03 400.63% | 0.05 75.69% | 0.05 2.59% | |
debt to equity | 0.30 - | 0.67 126.67% | 0.01 98.91% | 0.04 431.53% | 0.07 70.76% | 0.07 0.68% | |
dividend yield | |||||||
earnings yield | 0.00 - | -0.00 883.14% | 0.02 9,833.18% | 0.04 109.64% | 0.05 41.06% | -0.09 261.51% | |
enterprise value | 12.68B - | 12.69B 0.05% | 5.82B 54.14% | 3.50B 39.78% | 2.58B 26.27% | 1.60B 38.25% | |
enterprise value over ebitda | 7.04K - | -37.24K 628.93% | 34.24 100.09% | 14.45 57.80% | 9.35 35.28% | -8.30 188.77% | |
ev to operating cash flow | 3.56K - | 4.71K 32.41% | 256.41 94.56% | 14.33 94.41% | 9.31 34.98% | -36.36 490.34% | |
ev to sales | 1.44K - | 1.09K 23.91% | 24.95 97.72% | 9.34 62.58% | 5.32 43.01% | 41.95 688.29% | |
free cash flow per share | -0.01 - | -0.01 25.19% | 0.05 932.45% | 0.67 1,240.30% | 0.72 6.39% | -0.42 158.46% | |
free cash flow yield | -0.00 - | -0.00 25.19% | 0.00 1,318.46% | 0.05 3,671.58% | 0.07 50.19% | -0.07 203.71% | |
graham net net | 0.02 - | -0.01 165.08% | 3.64 32,790.43% | 2.00 45.09% | 2.13 6.77% | 1.64 23.28% | |
graham number | 0.04 - | 0.11 162.98% | 9.36 8,437.61% | 6.82 27.12% | 7.36 7.81% | 6.74 8.43% | |
income quality | 11.54 - | -1.22 110.56% | 0.19 115.66% | 1.59 735.28% | 1.75 9.78% | 0.30 82.87% | |
intangibles to total assets | 0 - | 0 | 0.15 Infinity% | 0.15 2.02% | 0.12 21.80% | 0.11 2.85% | |
interest coverage | -3.55 - | -19.68 454.08% | 23.96 221.77% | 39.12 63.25% | 53.53 36.82% | ||
interest debt per share | 0.02 - | 0.03 94.28% | 0.08 140.40% | 0.16 107.27% | 0.30 84.34% | 0.27 11.61% | |
inventory turnover | 19.28 - | 27.22 41.21% | 43.37 59.30% | ||||
invested capital | 0.30 - | 0.67 126.67% | 0.01 98.91% | 0.04 431.53% | 0.07 70.76% | 0.07 0.68% | |
market cap | 12.69B - | 12.69B 0% | 6.41B 49.51% | 3.94B 38.44% | 2.89B 26.77% | 1.65B 42.82% | |
net current asset value | 5.28M - | -595.59K 111.28% | 638.30M 107,271.44% | 636.96M 0.21% | 717.86M 12.70% | 536.21M 25.30% | |
net debt to ebitda | -3.89 - | 1.94 149.98% | -3.46 278.10% | -1.81 47.60% | -1.10 39.26% | 0.29 126.43% | |
net income per share | 0.00 - | -0.01 883.14% | 0.75 6,749.63% | 0.56 25.50% | 0.56 0.07% | -0.51 191.04% | |
operating cash flow per share | 0.02 - | 0.01 24.44% | 0.14 1,039.80% | 0.89 522.28% | 0.97 9.70% | -0.15 115.59% | |
payables turnover | 1.36 - | 1.42 4.78% | 2.00 40.97% | ||||
receivables turnover | 2.12 - | 2.65 25.17% | 1.09 58.78% | 2.34 113.70% | 12.58 438.30% | 0.59 95.30% | |
research and ddevelopement to revenue | 0.66 - | 0.87 32.54% | 0.13 85.53% | 0.17 31.21% | 0.22 34.36% | 4.62 1,978.66% | |
return on tangible assets | 0.01 - | -0.10 816.59% | 0.14 234.39% | 0.14 1.25% | 0.12 14.85% | -0.11 195.27% | |
revenue per share | 0.04 - | 0.05 31.49% | 1.46 2,617.07% | 1.36 7.10% | 1.70 25.16% | 0.13 92.28% | |
roe | 0.03 - | -0.24 986.80% | 0.14 160.66% | 0.15 4.49% | 0.13 14.09% | -0.13 198.84% | |
roic | 0.16 - | -0.22 242.70% | 0.14 162.72% | 0.13 7.17% | 0.10 20.61% | -0.15 248.07% | |
sales general and administrative to revenue | 0.24 - | 0.24 2.81% | 0.05 78.42% | 0.11 118.34% | 0.11 2.48% | 1.60 1,303.46% | |
shareholders equity per share | 0.05 - | 0.05 11.69% | 5.22 10,861.62% | 3.72 28.70% | 4.33 16.31% | 3.98 7.89% | |
stock based compensation to revenue | 0.07 - | 0.08 10.09% | 0.04 53.03% | 0.08 126.79% | 0.10 24.80% | 1.69 1,555.90% | |
tangible asset value | 11.61M - | 10.25M 11.69% | 683.86M 6,570.36% | 829.53M 21.30% | 1.05B 27.06% | 984.09M 6.63% | |
tangible book value per share | 0.05 - | 0.05 11.69% | 4.30 8,925.99% | 3.01 29.97% | 3.70 22.91% | 3.40 7.96% | |
working capital | 8.73M - | 4.75M 45.63% | 709.84M 14,858.14% | 809.12M 13.99% | 907.17M 12.12% | 752.97M 17.00% |
All numbers in USD (except ratios and percentages)